NCT05809869View on ClinicalTrials.gov

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Durvalumab

Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles

DRUG

Tremelimumab

Tremelimumab 300mg intravenous infusion on week 1 only.

RADIATION

Yttrium-90 radioembolisation

Yttrium-90 radioembolisation on week 2 only.

Trial Locations (1)

Unknown

RECRUITING

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong

All Listed Sponsors
collaborator

Queen Mary Hospital, Hong Kong

OTHER

lead

The University of Hong Kong

OTHER